109 related articles for article (PubMed ID: 8145276)
1. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and accumulation of an extremely stable high-energy phosphate compound by muscle, heart, and brain of animals fed the creatine analog, 1-carboxyethyl-2-iminoimidazolidine (homocyclocreatine).
Roberts JJ; Walker JB
Arch Biochem Biophys; 1983 Feb; 220(2):563-71. PubMed ID: 6824340
[TBL] [Abstract][Full Text] [Related]
3. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of analgo of phosphocreatine in muscle of chicks fed 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine).
Griffiths GR; Walker JB
J Biol Chem; 1976 Apr; 251(7):2049-54. PubMed ID: 1270421
[TBL] [Abstract][Full Text] [Related]
5. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
6. Relative abilities of phosphagens with different thermodynamic or kinetic properties to help sustain ATP and total adenylate pools in heart during ischemia.
Turner DM; Walker JB
Arch Biochem Biophys; 1985 May; 238(2):642-51. PubMed ID: 3994395
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
8. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Mulvaney PT; Stracke ML; Nam SW; Woodhouse E; O'Keefe M; Clair T; Liotta LA; Khaddurah-Daouk R; Schiffmann E
Int J Cancer; 1998 Sep; 78(1):46-52. PubMed ID: 9724093
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Matthews RT; Yang L; Jenkins BG; Ferrante RJ; Rosen BR; Kaddurah-Daouk R; Beal MF
J Neurosci; 1998 Jan; 18(1):156-63. PubMed ID: 9412496
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle studies of cyclocreatine, a new anticancer agent.
Martin KJ; Winslow ER; Kaddurah-Daouk R
Cancer Res; 1994 Oct; 54(19):5160-5. PubMed ID: 7923134
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis.
Kornacker M; Schlattner U; Wallimann T; Verneris MR; Negrin RS; Kornacker B; Staratschek-Jox A; Diehl V; Wolf J
Int J Cancer; 2001 Nov; 94(4):513-9. PubMed ID: 11745437
[TBL] [Abstract][Full Text] [Related]
12. Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine.
Martin KJ; Vassallo CD; Teicher BA; Kaddurah-Daouk R
Anticancer Drugs; 1995 Jun; 6(3):419-26. PubMed ID: 7670140
[TBL] [Abstract][Full Text] [Related]
13. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
Kristensen CA; Askenasy N; Jain RK; Koretsky AP
Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
[TBL] [Abstract][Full Text] [Related]
14. Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
Bergnes G; Yuan W; Khandekar VS; O'Keefe MM; Martin KJ; Teicher BA; Kaddurah-Daouk R
Oncol Res; 1996; 8(3):121-30. PubMed ID: 8823808
[TBL] [Abstract][Full Text] [Related]
15. Cyclocreatine in cancer chemotherapy.
Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
17. Liposomal Delivery of Cyclocreatine Impairs Cancer Cell Bioenergetics Mediating Apoptosis.
Ganguly S; Elbayoumi T
Methods Mol Biol; 2021; 2275():173-186. PubMed ID: 34118038
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatographic assays for free and phosphorylated derivatives of the creatine analogues beta-guanidopropionic acid and 1-carboxy-methyl-2-iminoimidazolidine (cyclocreatine).
Wiseman RW; Moerland TS; Chase PB; Stuppard R; Kushmerick MJ
Anal Biochem; 1992 Aug; 204(2):383-9. PubMed ID: 1443539
[TBL] [Abstract][Full Text] [Related]
19. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses.
Lillie JW; Smee DF; Huffman JH; Hansen LJ; Sidwell RW; Kaddurah-Daouk R
Antiviral Res; 1994 Apr; 23(3-4):203-18. PubMed ID: 8042860
[TBL] [Abstract][Full Text] [Related]
20. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
